A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2019
Price : $35 *
At a glance
- Drugs Ceralasertib (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 18 Sep 2019 Status changed from not yet recruiting to recruiting.
- 25 Jun 2019 Planned initiation date changed from 31 Mar 2018 to 31 Jul 2019.
- 05 Mar 2019 Planned initiation date changed from 31 Dec 2018 to 31 Mar 2018.